Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong growth expectations, strategic expense reductions, and new product launches. Despite some uncertainties in data timelines, the company's expansion plans and profitability targets are promising. Positive sentiment is reinforced by planned product launches and market expansion efforts.
Key Financial Performance
Total Revenue (Q1 2026) $136 million, with contributions from Crysvita ($93 million), Dojolvi ($18 million), Evkeeza ($18 million, 64% growth YoY), and Mepsevii ($7 million). Reasons for changes include steady demand growth for Dojolvi and Evkeeza's growth due to launches outside the U.S.
Crysvita Revenue (Q1 2026) $93 million, including $39 million from North America, $46 million from Latin America and Turkey, and $8 million from Europe. Revenue was consistent with anticipated quarterly timing and trends.
Dojolvi Revenue (Q1 2026) $18 million, reflecting steady demand growth. North America saw more than 30 start forms, exceeding targets, with over 675 patients on reimbursed therapy.
Evkeeza Revenue (Q1 2026) $18 million, representing 64% growth YoY. Growth attributed to launches in territories outside the U.S. and increasing demand.
Mepsevii Revenue (Q1 2026) $7 million, attributed to continued treatment of patients in this ultrarare indication.
Operating Expenses (Q1 2026) $305 million, including $30 million in cost of sales and $275 million in combined R&D and SG&A expenses. Included $30 million of non-cash stock-based compensation and $30 million related to restructuring.
Net Loss (Q1 2026) $185 million or $1.84 per share. Reasons include high operating expenses and restructuring costs.
Cash Position (March 31, 2026) $534 million in cash, cash equivalents, and marketable securities. Net cash used in operations was $197 million, influenced by annual bonus payments and manufacturing/severance costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GTX-102 for Angelman syndrome: Phase 3 Aspire study is ongoing, with patients transitioning to open-label extension. Aurora study is expanding treatment to other ages and genotypes. Long-term data shows clinically meaningful treatment effects and safety.
Dojolvi: Steady growth with over 675 patients in North America and 300 in Europe. Conditional approval in Japan, with full approval and launch expected this quarter.
Evkeeza: Exceptional growth outside the U.S., with 370 patients across 18 countries. Expected to be a growing revenue contributor.
DTX401 and UX111: Launch readiness underway for DTX401 (PDUFA date: August 23, 2026) and UX111 (PDUFA date: September 19, 2026).
Global commercial reach: Revenue generated in over 35 countries, reflecting strategic investments in high-quality teams for approval and reimbursement processes.
Crysvita: Revenue of $93 million in Q1 2026, with over 950 patients in Latin America. Strong demand across regions.
Revenue growth: On track to exceed $700 million in 2026, with 8%-13% growth over 2025.
Operational expenses: Total operating expenses for Q1 2026 were $305 million, with a pathway to profitability by 2027.
Focus on rare diseases: Developing first-ever treatments for diseases with no significant breakthroughs, leveraging advanced molecular genetics.
Manufacturing capabilities: Gene therapy products being manufactured in a new facility in Bedford, Massachusetts.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Variability: Revenue in certain regions, such as Brazil, is subject to variability due to bulk orders by the Ministry of Health, which can impact quarter-to-quarter financial performance.
High Operating Expenses: Total operating expenses for the quarter were $305 million, including significant costs related to R&D, SG&A, and restructuring, which could pressure profitability.
Cash Flow Challenges: Net cash used in operations for the quarter was $197 million, with additional payments for manufacturing activities and severance, indicating potential liquidity concerns.
Regulatory Risks: The company is awaiting FDA approvals for key products (DTX401 and UX111) with PDUFA dates later in the year, and any delays or negative outcomes could impact strategic objectives.
Product Launch Risks: The company is preparing for two new product launches, which require significant readiness efforts and could face challenges in execution or market adoption.
Supply Chain and Manufacturing Costs: Payments related to UX143 manufacturing activities and the establishment of a new facility in Bedford, Massachusetts, indicate potential risks in managing supply chain and production costs.
Dependence on Key Products: Revenue heavily relies on a few key products like Crysvita, Dojolvi, and Evkeeza, making the company vulnerable to market or regulatory changes affecting these products.
Economic and Reimbursement Challenges: Navigating complex approval and reimbursement processes in multiple countries poses risks, especially in regions with variable economic conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Total revenue is expected to be between $730 million and $760 million, representing 8% to 13% growth over 2025. Crysvita revenue is projected to be between $500 million and $520 million, while Dojolvi revenue is expected to range from $100 million to $110 million.
Pathway to Profitability: The company aims to achieve profitability by 2027, with combined R&D and SG&A expenses expected to decrease at least 15% in 2027 compared to 2025.
Product Launches: Two new product launches are anticipated in 2026: DTX401 with a PDUFA date of August 23, 2026, and UX111 with a PDUFA date of September 19, 2026. Launch readiness work is underway for both programs.
GTX-102 for Angelman Syndrome: Top-line Phase 3 data from the Aspire study is expected in the second half of 2026. The drug has shown promising long-term safety and efficacy in Phase 1/2 studies, with continued improvement across multiple developmental domains.
Global Commercial Expansion: The company is preparing for the full approval and launch of Dojolvi in Japan in 2026. Additionally, Evkeeza is expected to continue its growth trajectory, with 370 patients across 18 countries currently receiving the treatment.
Gene Therapy Approvals: Two gene therapies are under review, with PDUFA dates set for 2026. These therapies aim to address unmet needs in rare diseases, potentially accelerating the company's growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you comment on the new update for Angelman, specifically the consistency of patient improvements on the Bayley-4 and MDRI endpoints for Phase 3?
A:The Bayley-4 test is being conducted with high-quality operations to reduce variability. Consistency cannot be commented on for Phase 3 yet, but Phase 2 results showed strong and consistent outcomes, particularly with MDRI. The inclusion of patients with full deletions in Phase 3 is expected to drive consistent results.
Q:Are you stratifying randomization or prespecifying subgroups by baseline factors in the Aspire trial for GTX-102?
A:Yes, randomization is stratified by age and cognitive raw score to ensure consistent balance in the Aspire trial.
Q:When can we expect Aspire top-line data for GTX-102?
A:The data is expected in the second half of 2026. The exact timing is not specified due to the complexity of closing out an international study with multiple endpoints.
Q:Could we see detailed Phase 1/2 data for Angelman ahead of Phase 3 top-line results?
A:Detailed Phase 1/2 data is unlikely to be released ahead of Phase 3 results. The company has not set a plan for presenting Phase 2 data but aims to provide confidence in the drug's safety and cognitive benefits.
Q:Will there be discussions with the FDA on the magnitude of improvement on primary endpoints for Angelman before database lock?
A:No regulatory steps are required before unblinding. The Bayley-4 cognition endpoint is based on continuous analysis, and the expected improvement is well above the clinically important change threshold.
Q:What is the status of commercial manufacturing and readiness for the upcoming gene therapy launches, DTX401 and UX111?
A:Manufacturing has been ongoing since last year. DTX401 and UX111 are being produced at different facilities, and inventory is being built. Launch teams are preparing, and qualified treatment centers are being set up.
Q:What are the timelines for data from the Aurora study, and how will it impact the Angelman label?
A:The Aurora study is still enrolling and aims to expand the label to other genotypes and ages. The main Aspire study focuses on ages 4-17 with full deletions. Plans for filing and launch will depend on the data.
Q:Why might there be more than one maintenance dose for GTX-102, and what is the expected label dose?
A:The expected maintenance dose is 14 mg every 3 months. In a commercial setting, dosing may be explored further, but the current plan is based on FDA discussions.
Q:What are the profitability projections and assumptions for PRV monetization?
A:Two PRVs are planned for monetization, each modeled at over $100 million. Profitability post-2027 is expected to grow, depending on launch success and reinvestment decisions.
Q:What is the path forward if MDRI hits but Bayley-4 does not in the Angelman Phase 3 trial?
A:A positive MDRI and a missed Bayley-4 would still be considered a positive study. The MDRI provides a robust measure of efficacy, and the FDA has agreed to this approach.
Q:How does the Phase 1/2 Angelman data inform the Phase 3 Aspire trial design?
A:Phase 1/2 data, particularly from cohorts A and B, aligns with the Phase 3 design in terms of patient type and sites. The data supports the dosing regimen and techniques used in Phase 3.
Q:What is the contribution of caregiver input to Bayley-4 cognition in the Angelman trials?
A:Caregiver input is not included in the Bayley-4 cognition primary endpoint for Phase 3, per FDA request. Phase 1/2 included caregiver input, but its impact on results is minimal.
Q:What are the expectations for sham performance in the Aspire study for Angelman?
A:Sham performance is expected to align with natural history data, showing minimal change in Bayley-4 cognition scores for deletion patients.
Q:What are the differences between the new GNE myopathy molecule and the previous one?
A:The new molecule is a prodrug with enhanced hydrophobicity, allowing better uptake into muscle cells and effective sialic acid replacement. The previous molecule failed due to poor penetration.
Q:What is the relative level of conviction on Bayley-4 cognition versus MDRI for Angelman?
A:MDRI is considered more powerful due to its multiple endpoints, but Bayley-4 cognition has sufficient power allocated. The current protocol balance is deemed appropriate.
Q:What are the plans for reducing discontinuation rates for GTX-102 in the commercial setting?
A:Discontinuation rates are expected to be low in the commercial setting. Efforts will focus on improving accessibility and convenience, potentially with new devices for intrathecal delivery.
Q:Review of Unclear Management Responses
A:Management avoided providing a precise timeline for Aspire top-line data, citing the complexity of closing out an international study. They also did not specify when detailed Phase 1/2 data for Angelman would be presented, leaving it uncertain whether it will be available before Phase 3 results. Additionally, they did not provide clarity on the exact revenue expectations for the upcoming gene therapy launches, stating only that launch preparations are ongoing.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America patient
Angelman syndrome
Aspire study
Bayley score
Chief
Dojolvi
Emil
Evkeeza
GTX
MDRI
North America
Officer
PDUFA date
Phase Aspire
Phase program
Phase study
RD SGA
afternoon
approval
average
cash
cognition
country
demand
difference
disease
extension
infrastructure
label
launch
patient therapy
payment
region
team
treatment
year
RARE Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong growth expectations, strategic expense reductions, and new product launches. Despite some uncertainties in data timelines, the company's expansion plans and profitability targets are promising. Positive sentiment is reinforced by planned product launches and market expansion efforts.
Dorel Industries Inc. (DII.B:CA) Q4 2025 Earnings Call Transcript
Unknown3-11
The earnings call reveals several challenges, including supply chain disruptions, market volatility, legacy costs, and increased finance expenses. Despite some improvements in the Juvenile segment, the Home segment struggles with significant revenue decline and restructuring. The Q&A section highlights management's uncertainty regarding cost base and profitability timelines. These factors, combined with the broader economic challenges, suggest a negative outlook for the stock price over the next two weeks.
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
RARE Slides
RARE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
